Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy

被引:0
|
作者
Ehimen C. Aneni
Esteban Escolar
Gervasio A. Lamas
机构
[1] Mount Sinai Medical Center,Department of Medicine
[2] Columbia University Division of Cardiology,undefined
[3] Mount Sinai Medical Center,undefined
来源
关键词
Edetate disodium; Chelation; Myocardial infarction; Lead toxicity; Trial to Assess Chelation Therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Over the last few decades, there has been a growing body of epidemiologic evidence linking chronic toxic metal exposure to cardiovascular disease-related morbidity and mortality. The recent and unexpectedly positive findings from a randomized, double-blind, multicenter trial of metal chelation for the secondary prevention of atherosclerotic cardiovascular disease (Trial to Assess Chelation Therapy (TACT)) have focused the discussion on the role of chronic exposure to toxic metals in the development and propagation of cardiovascular disease and the role of toxic metal chelation therapy in the secondary prevention of cardiovascular disease. This review summarizes the most recent evidence linking chronic toxic metal exposure to cardiovascular disease and examines the findings of TACT.
引用
收藏
相关论文
共 50 条
  • [1] Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy
    Aneni, Ehimen C.
    Escolar, Esteban
    Lamas, Gervasio A.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (12)
  • [2] Heavy Metal Toxicity in Chronic Renal Failure and Cardiovascular Disease Possible Role for Chelation Therapy
    Glicklich, Daniel
    Shin, Christopher T.
    Frishman, William H.
    [J]. CARDIOLOGY IN REVIEW, 2020, 28 (06) : 312 - 318
  • [3] Metal pollutants and cardiovascular disease: Mechanisms and consequences of exposure
    Solenkova, Natalia V.
    Newman, Jonathan D.
    Berger, Jeffrey S.
    Thurston, George
    Hochman, Judith S.
    Lamas, Gervasio A.
    [J]. AMERICAN HEART JOURNAL, 2014, 168 (06) : 812 - 822
  • [4] Chelation therapy for atherosclerotic cardiovascular disease
    Vanessa Villarruz-Sulit, Maria
    Forster, Rachel
    Dans, Antonio L.
    Tan, Flordeliza N.
    Sulit, Dennis, V
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (05):
  • [5] Chelation therapy in cardiovascular disease: an update
    Sultan, Sulaiman
    Murarka, Shishir
    Jahangir, Ahad
    Mookadam, Farouk
    Tajik, A. Jamil
    Jahangir, Arshad
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 843 - 854
  • [6] Metal chelation therapy for Alzheimer disease
    Rosenberg, RN
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (12) : 1678 - 1679
  • [7] Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease An Emerging Role for Evolocumab?
    Cherney, David Z. I.
    Rosenson, Robert S.
    Lawler, Patrick R.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (23) : 2971 - 2975
  • [8] Role of EDTA chelation therapy in cardiovascular diseases
    Shrihari, JS
    Roy, A
    Prabhakaran, D
    Reddy, KS
    [J]. NATIONAL MEDICAL JOURNAL OF INDIA, 2006, 19 (01): : 24 - 26
  • [9] EFFECT OF CHELATION THERAPY ON CARDIOVASCULAR EVENTS BY CHRONIC KIDNEY DISEASE STAGE: DATA FROM THE TRIAL TO ASSESS CHELATION THERAPY (TACT)
    Ouyang, Pamela
    Lamas, Gervasio
    Nahin, Richard
    Gallup, Dianne
    Boineau, Robin
    Rosenberg, Yves
    Mark, Daniel
    Goertz, Christine
    Lee, Kerry
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A1537 - A1537
  • [10] Chelation therapy for cardiovascular disease - Review and commentary
    Lewin, MR
    [J]. TEXAS HEART INSTITUTE JOURNAL, 1997, 24 (02) : 81 - 89